Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer have?
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer has 1,618 citations in the OpenAlex counts ScholarIQ stores.
When was Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer published?
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer has 2019 year in the ScholarIQ index.
What is the open-access status of Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer?
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer has closed oa status in the ScholarIQ index.
What is the DOI of Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer?
The DOI for Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer is on the source record.
What is the PMID of Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer?
The PMID for Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer is on the source record.
What is the OpenAlex record for Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer?
The OpenAlex for Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer is on the source record.